CD38 Assay Service
●
Target
CD38
●
Description
Screening and/or profiling inhibitor compounds against CD38 hydrolase activity in a biochemical assay.
●
Synonyms
cyclic ADP ribose hydrolase
●
Example Data
*Example only, final data may vary.
Assay Details
●
Assay Format
Fluorogenic
●
Reference Compounds and IC50
Apigenin, 8.5 μM
●
Assay Principle
The CD38 Inhibitor Screening Assay is designed to measure the glycohydrolase activity of CD38 for screening and profiling applications. The CD38 assay is performed in a 96-well format, with purified recombinant CD38 enzyme and its substrate N6-etheno-NAD (ε-NAD), which is then measured using fluorescence.
Target Details
●
Protein Family
Immunotherapy
●
UniProt
P28907
●
Background
CD38, a differentiation antigen of B lymphocytes, is a type II integral membrane protein. It is also known as ADP-ribosyl cyclase and nicotinamide adenine dinucleotide (NAD) glycohydrolase. Through its production of cyclic ADP-ribose, CD38 modulates calcium-mediated signal transduction in various cells, including pancreatic β cells. The major enzymatic activity of CD38 is the hydrolysis of NAD. CD38 is a prognostic biomarker for acute B lymphoblastic leukemia.
Delivery
●
Estimated Turnaround
Two to three weeks following delivery of compounds
●
Results
Extensive report with raw and analyzed data, graphs, and detailed protocols. Includes positive control for inhibition.
